Pharmacokinetic properties of IB1001, an investigational recombinant factor IX, in patients with haemophilia B: Repeat pharmacokinetic evaluation and sialylation analysis

Haemophilia

Volumn 18, Issue 6, 2012, Pages 881-887

  Martinowitz, U ^a   Shapiro, A ^b   Quon, D V ^c   Escobar, M ^d   Kempton, C ^e   Collins, P W ^f   Chowdary, P ^g   Makris, M ^h   Mannucci, P M ⁱ   Morfini, M ^j   Valentino, L A ^k   Gomperts, E ^l   Lee, M ^l  

^a SHEBA MEDICAL CENTER   (Israel)

^b INDIANA HEMOPHILIA AND THROMBOSIS CENTER   (United States)

^c JOINT REPLACEMENT INSTITUTE   (United States)

^d UNIVERSITY OF TEXAS   (United States)

^e EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f CARDIFF UNIVERSITY   (United Kingdom)

^g ROYAL FREE HOSPITAL   (United Kingdom)

^h ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

ⁱ FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^j CAREGGI UNIVERSITY HOSPITAL   (Italy)

^k RUSH UNIVERSITY MEDICAL CENTER   (United States)

^l Inspiration Biopharmaceuticals   (United States)

more..

Author keywords

Blood coagulation factor; Haemophilia B; IB1001; Pharmacokinetics; Recombinant factor IX; Sialylation

Indexed keywords

BLOOD CLOTTING FACTOR 9; D DIMER; FIBRIN; PROTHROMBIN; RECOMBINANT BLOOD CLOTTING FACTOR 9; THROMBIN ANTITHROMBIN COMPLEX;

ADOLESCENT; ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; BODY WEIGHT; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; HEMARTHROSIS; HEMOPHILIA B; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; OUTCOME ASSESSMENT; PATIENT MONITORING; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROPHYLAXIS; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; SIALYLATION; SIDE EFFECT; STEADY STATE; THROMBOGENICITY;

ADOLESCENT; ADULT; AREA UNDER CURVE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FACTOR IX; HALF-LIFE; HEMOPHILIA B; HUMANS; MALE; MIDDLE AGED; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; SIALIC ACIDS; YOUNG ADULT;

EID: 84868204378     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2012.02897.x     Document Type: Article

References (16)

1. Ingerslev J. Pharmacovigilence studies in haemophilia. Haemophilia 2007; 13: 121-3.
2. National Hemophilia Foundation. Hemophilia B (Factor IX). Available at: http://www.hemophilia.org/NHFWeb/MainPgs/MainNHF.aspx?menuid=181&contentid=46&rptname=bleeding. Accessed 21 October 2011.
3. Bolton-Maggs PH, Pasi KJ. Haemophilias A and B. Lancet 2003; 361: 1801-9.
4. Giangrande P. Hemophilia B: Christmas disease. Expert Opin in Pharmacother 2005; 6: 1517-24.
5. Gater A, Thomson TA, Strandberg-Larsen M. Haemophilia B: impact on patients and economic burden of disease. Thromb Haemost 2011; 106: 398-404.
6. Berntorp E, Boulyjenkov V, Brettler D et al. Modern treatment of haemophilia. Bull World Health Organ 1995; 73: 691-701.
7. Roth DA, Kessler CM, Pasi KJ, Rup B, Courter SG, Tubridy KL, Recombinant Factor IX Study Group. Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates. Blood 2001; 98: 3600-6.
8. Griffith MJ, Monroe DM, KE van Cott et al. N-Glycan sialylation is important for in vivo recovery of recombinant factor IX. J Thromb Haemost 2007; 5: P-M-043.
9. World Medical Association. Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects. 2008. Available at: http://www.wma.net/en/30publications/10policies/b3/17c.pdf. Accessed January 7, 2011.
10. Morfini M, Lee M, Messori A. The design and analysis of half-life and recovery studies for factor VIII and factor IX. Factor VIII/Factor IX Scientific and Standardization Committee of the International Society for Thrombosis and Haemostasis. Thromb Haemost 1991; 66: 384-6.
11. Lee M, Morfini M, Schulman S, Ingerslev J and the Factor VIII/Factor IX. Scientificand Standardization Committee of the International Society for Thrombosisand Haemostasis. The design and analysis of pharmacokinetic studies of coagulation factors. Available at: http://isth.org/default/assets/File/fviiipharmaco.pdf. Accessed January 3, 2012.
12. Lee ML, Poon W-Y, Kingdon HS. A two-phase linear regression model for biological half-life data. J Lab Clin Med 1990; 115: 745-8.
13. Lee ML, Schroth P, Bray G, Gomperts ED. The use of robust regression techniques to obtain improved coagulation factor half-life estimates. XVIth Congress of the International Society on Thrombosis and Haemostasis, Florence, Italy, 1997 (abstract).
14. Björkman S, Carlsson M. The pharmacokinetics of factor VIII and factor IX: methodology, pitfalls and applications. Haemophilia 1997; 3: 1-8.
15. BeneFIX [Coagulation Factor IX (Recombinant)] Prescribing Information. Pfizer, Inc. August 2011. Available at: http://labeling.pfizer.com/showlabeling.aspx?id=492. Accessed 05 December 2011.
16. Köhler M. Thrombogenicity of prothrombin complex concentrates. Thromb Res 1999; 4: S13-7.